
    
      The purpose of this study is to establish the safety profile and the maximum tolerated dose
      (MTD) of the fully human anti-EGFR monoclonal antibody IMC-11F8 in patients with solid tumors
      who have filed standard therapy or for whom no standard therapy is available.
    
  